Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study

Table 1

Patient characteristics (safety population, ).

	Patient number (percentage)
Sex
Female	18 (39.1%)
Male	28 (60.9%)
(years)
Mean (SD)	52.4 (13.24)
Median	53
(Minimum/maximum)	(25–79)
Weight (kg) in hospital versus at home
Mean (SD)	74.3 (14.6) versus 74.5 (14.5)
Median	74.2 versus 75
(Minimum/maximum)	(49–127) versus (50–126)
Autoimmune diseases
Motor multifocal neuropathy (MMN)	21 (45.7%)
Chronic inflammatory demyelinating polyneuropathy including Lewis-Sumner syndrome	12 (26.1%)
Polymyositis	3 (6.5%)
Dermatomyositis	3 (6.5%)
Body inclusion myositis	3 (6.5%)
Sclerosis with myopathy	1 (2.2%)
Gougerot-Sjogren syndrome with neurological forms	1 (2.2%)
Myasthenia gravis	1 (2.2%)
Cutaneous polyarteritis nodosa	1 (2.2%)
Family situation
Living in a couple or in a family setting	41 (89.1%)
Living alone	5 (10.9%)
Professional activity at the time of administration of the cycles in hospital
Professional activity	19 (42.2%)
Without professional activity	26 (57.8%)
(i) Retired person	17
(ii) Disabled person	6
(iii) Sick leave	1
(iv) Other	2

SD: standard deviation. age = patient’s age at the time of the last hospital-based cycle of Tegeline before starting treatment at home.